About Us
Intellectual Property
NeuroRepair, Inc. owns two issued patents and other pending patent applications, respecting methods of treatmentsof central nervous system disorders and injuries, including stroke, Alzheimer’s disease, Parkinson disease, spinal cord injury, retinal disorders, and brain injury from head trauma.
- United States Patent 7,790,669
- United States Patent No.: us 7,795,202 B2
- In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain
- Intranasal Administration of PEGylated Transforming Growth Factor-α Improves Behavioral Deficits in a Chronic Stroke Model
- Neuroscience 156 (2008) 81–88
- Neuroscience 160 (2009) 470–483
- The Strategic News Service ® Newsletter Volume 13, Issue 12
Pipeline
Transforming Growth Factor-alpha
TGFα is an endogenous 50 amino acid growth factor with no posttranslational modifications. TGFα has been shown to protect against acute neuronal cell death in animal models of stroke. NeuroRepair is currently developing TGFα applications for the treatment of acute and chronic stroke and plans to begin preclinical testing in primates.
Preview Our Process and Results
Future Indications
TGFα also induces massive proliferation, migration
and differentiation of new neurons in the damaged adult brain. The degree
of proliferation and migration is orders of magnitude over any other growth
factor or synthetic small molecule.
In the long term, NeuroRepair plans to develop applications respecting
the use of TGFa for treatment of central nervous system disorders and
injuries, including stroke, Alzheimer’s disease, Parkinson disease, spinal
cord injury, retinal disorders, and brain injury from head trauma.
Figure 3
Rats receiving an infusion
of TGFa after brain injury to the striatum (cartooned in purple) demonstrate
massive proliferation of stem cells in the subventricular zone (SVZ) which
migrate in a ridge toward the site of the injury. New cells express markers
of differentiating glial cells and neurons. Adapted from Fallon et al., 2000
2006 , 2010 © NeuroRepair, Inc. All rights reserved.
Preview Our Process and Results
Fig. 3. Further characterization of the TGF -induced striatal ridge cells. (a) Cross section of pseudocolor autoradiographic image (EGFr-mRNA) showing SVZ, location of a ridge, a smaller ridge in the corpus callosum (CC), and a cartoon image of the TGF infusion cannula (white line) and infusion site in the right caudate putamen (pink circle). (b) The ridge cells (arrows) are nestin-positive, showing that they are neural progenitors. (c) Silver staining shows a fusiform morphology of the cells in the ridge (outlined by white lines), suggestive of outward migration from the SVZ lining the lateral ventricle (lv). (d) BrdUrd was incorporated by SVZ (arrows) and ridge cells laterally in the striatum, but not in the septum (S) after a striatal TGF infusion. (e) Some migrating cells subsequently stained positive for -III tubulin, a marker for neuronal restricted lineage. (f) Longer TGF infusion times revealed increasing numbers of TH-positive neurons (higher magnification in g).